W. Douglas Fairlie

20.4k citations

103 papers · 8.7k indexed · 3 hit papers · h-index 45

Molecular Biology top 1%
Immunology top 1%
Rheumatology top 0.5%
Oncology top 2%
Physiology top 1%

Co-authors: Erinna F. Lee David C.S. Huang Samuel N. Breit Peter E. Czabotar Peter M. Colman Asne R. Bauskin Brian J. Smith Philippe Bouillet
Topics: Cell death mechanisms and regulation (37 papers)RNA Interference and Gene Delivery (17 papers)GDF15 and Related Biomarkers (11 papers)
Cited by: Rheumatology Immunology Molecular Biology
Journals: Nature Science Cell
Partner nations: Australia United States Italy

In The Last Decade

W. Douglas Fairlie

102 papers receiving 8.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily

1997 956 citations Asne R. Bauskin, Stella M. Valenzuela et al. Proceedings of the National Academy of Sciences profile →
Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak

2007 883 citations Jamie I. Fletcher, Erinna F. Lee et al. profile →
Bax Crystal Structures Reveal How BH3 Domains Activate Bax and Nucleate Its Oligomerization to Induce Apoptosis

2013 444 citations W. Douglas Fairlie, Erinna F. Lee et al. profile →

Peers

Countries citing papers authored by W. Douglas Fairlie

Since Specialization

Citations

This map shows the geographic impact of W. Douglas Fairlie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Douglas Fairlie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Douglas Fairlie more than expected).

Fields of papers citing papers by W. Douglas Fairlie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Douglas Fairlie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Douglas Fairlie. The network helps show where W. Douglas Fairlie may publish in the future.

Co-authorship network of co-authors of W. Douglas Fairlie

This figure shows the co-authorship network connecting the top 25 collaborators of W. Douglas Fairlie. A scholar is included among the top collaborators of W. Douglas Fairlie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Douglas Fairlie. W. Douglas Fairlie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development of a Novel Biomarker Platform for Profiling Key Protein–Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs 2025 ·Cancers ·(unknown),(unknown),(unknown),(unknown),Bora Lim,Stephanie J. Bouley,James A. Walker,Erinna F. Lee,W. Douglas Fairlie,Kevin R. Kelly,(unknown)	1
2	Combination of bazedoxifene with chemotherapy and SMAC-mimetics for the treatment of colorectal cancer 2024 ·Cell Death and Disease ·(unknown),Michelle Palmieri,(unknown),Larissa Doughty,Tracy L. Nero,Ashleigh R. Poh,Sarah Q. To,Erinna F. Lee,W. Douglas Fairlie,Lisa A. Mielke,Michael W. Parker,Ivan K. H. Poon,Eduard Batlle,Matthias Ernst,Ashwini L. Chand	5
3	BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAFV600E colorectal cancer 2024 ·Cell Death and Disease ·Laura J. Jenkins,Ian Y. Luk,Fiona Chionh,Tao Tan,(unknown),(unknown),(unknown),(unknown),Oliver M. Sieber,Dmitri Mouradov,Peter Gibbs,David S. Williams,Niall C. Tebbutt,Jayesh Desai,Frédéric Hollande,Amardeep S. Dhillon,Erinna F. Lee,Delphine Mérino,W. Douglas Fairlie,John M. Mariadason	4
4	Differential membrane binding of a/ß-peptide foldamers: implications for cellular delivery and mitochondrial targeting 2023 ·Australian Journal of Chemistry ·Tzong-Hsien Lee,James W. Checco,(unknown),(unknown),Ronald T. Raines,Samuel H. Gellman,Erinna F. Lee,W. Douglas Fairlie,Marie‐Isabel Aguilar	3
5	Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer 2021 ·International Journal of Molecular Sciences ·W. Douglas Fairlie,Erinna F. Lee	28
6	Diversity in the intrinsic apoptosis pathway of nematodes 2020 ·Communications Biology ·Neil D. Young,Tiffany J. Harris,Marco Evangelista,Sharon Tran,Merridee A. Wouters,Tatiana P. Soares da Costa,Nadia J. Kershaw,Robin B. Gasser,Brian J. Smith,Erinna F. Lee,W. Douglas Fairlie	2
7	BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival 2019 ·Cell Death and Disease ·Erinna F. Lee,Tiffany J. Harris,Sharon Tran,Marco Evangelista,Surein Arulananda,Thomas John,(unknown),(unknown),Haoran Zhu,Gency Gunasingh,David Segal,Andreas Behren,Jonathan Cebon,Alexander Dobrovic,John M. Mariadason,Andreas Strasser,Leona Rohrbeck,Nikolas K. Haass,Marco J. Herold,W. Douglas Fairlie	142
8	ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types 2017 ·Clinical Cancer Research ·Anderly C. Chüeh,Janson W.T. Tse,Michael Dickinson,(unknown),Laura J. Jenkins,Lars Tögel,(unknown),Ian Y. Luk,Mercedes Dávalos-Salas,(unknown),Matthew R. Thompson,Bryan Williams,Guillaume Lessène,Erinna F. Lee,W. Douglas Fairlie,Amardeep S. Dhillon,John M. Mariadason	44
9	Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia 2012 ·Genes & Development ·Stefan Glaser,Erinna F. Lee,(unknown),Philippe Bouillet,Andrew H. Wei,W. Douglas Fairlie,David J. Izon,Johannes Zuber,Amy Rappaport,Marco J. Herold,Warren S. Alexander,Scott W. Lowe,Lorraine Robb,Andreas Strasser	317
10	Functional genomics approaches in parasitic helminths 2011 ·Parasite Immunology ·Jana Hagen,Erinna F. Lee,W. Douglas Fairlie,Bernd H. Kalinna	21
11	The role of BH3-only protein Bim extends beyond inhibiting Bcl-2–like prosurvival proteins 2009 ·The Journal of Cell Biology ·Delphine Mérino,Maybelline Giam,Peter Hughes,Owen M. Siggs,Klaus Heger,Lorraine A. O’Reilly,Jerry M. Adams,Andreas Strasser,Erinna F. Lee,W. Douglas Fairlie,Philippe Bouillet	149
12	The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia 2009 ·Leukemia ·Kylie D. Mason,Seong Lin Khaw,Kathleen C. Rayeroux,Edward Chew,Erinna F. Lee,W. Douglas Fairlie,A. Grigg,John F. Seymour,Jeff Szer,David C.S. Huang,Andrew W. Roberts	78
13	Structural Insights into the Protease-like Antigen Plasmodium falciparum SERA5 and Its Noncanonical Active-Site Serine 2009 ·Journal of Molecular Biology ·Anthony N. Hodder,Robyn Malby,Oliver B. Clarke,W. Douglas Fairlie,Peter M. Colman,Brendan S. Crabb,Brian J. Smith	35
14	Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax 2008 ·Proceedings of the National Academy of Sciences ·Jamie I. Fletcher,(unknown),Christine J. Hawkins,David T. Riglar,Erinna F. Lee,W. Douglas Fairlie,David C.S. Huang,Jerry M. Adams	156
15	Affinity Maturation of Leukemia Inhibitory Factor and Conversion to Potent Antagonists of Signaling 2004 ·Journal of Biological Chemistry ·W. Douglas Fairlie,Alessandro D. Uboldi,(unknown),(unknown),Erinna F. Lee,Shenggen Yao,David P. De Souza,Sandra Mifsud,Donald Metcalf,Nicos A. Nicola,Raymond S. Norton,Manuel Baca	29
16	Recombinant CLIC1 (NCC27) Assembles in Lipid Bilayers via a pH-dependent Two-state Process to Form Chloride Ion Channels with Identical Characteristics to Those Observed in Chinese Hamster Ovary Cells Expressing CLIC1 2002 ·Journal of Biological Chemistry ·Kristina Warton,Raffaella Tonini,W. Douglas Fairlie,Jacqueline M. Matthews,Stella M. Valenzuela,Min Qiu,(unknown),(unknown),Asne R. Bauskin,S.J. Harrop,Terence J. Campbell,Paul M. G. Curmi,Samuel N. Breit,Michele Mazzanti	110
17	Crystal Structure of a Soluble Form of the Intracellular Chloride Ion Channel CLIC1 (NCC27) at 1.4-Å Resolution 2001 ·Journal of Biological Chemistry ·S.J. Harrop,Matthew Z. DeMaere,W. Douglas Fairlie,(unknown),Stella M. Valenzuela,Michele Mazzanti,Raffaella Tonini,Min Qiu,Lucy Jankova,Kristina Warton,Asne R. Bauskin,(unknown),(unknown),Terence J. Campbell,Samuel N. Breit,Paul M. G. Curmi	177
18	The Propeptide of the Transforming Growth Factor-β Superfamily Member, Macrophage Inhibitory Cytokine-1 (MIC-1), Is a Multifunctional Domain That Can Facilitate Protein Folding and Secretion 2001 ·Journal of Biological Chemistry ·W. Douglas Fairlie,Hongping Zhang,(unknown),(unknown),Asne R. Bauskin,Patricia K. Russell,Peter K. Brown,Samuel N. Breit	40
19	Expression of growth differentiation factor‐15/ macrophage inhibitory cytokine‐1 (GDF‐15/MIC‐1) in the perinatal, adult, and injured rat brain 2001 ·The Journal of Comparative Neurology ·Andreas Schober,Martina Böttner,Jens Strelau,Ralf Kinscherf,Gabriel A. Bonaterra,Martin Barth,Lothar Schilling,W. Douglas Fairlie,Samuel N. Breit,Klaus Unsicker	121
20	The propeptide of macrophage inhibitory cytokine (MIC-1), a TGF-β superfamily member, acts as a quality control determinant for correctly folded MIC-1 2000 ·The EMBO Journal ·Asne R. Bauskin,Hongping Zhang,W. Douglas Fairlie,Xiao Yan He,Patricia K. Russell,Anthony G. Moore,David A. Brown,Keith K. Stanley,Samuel N. Breit	109

About W. Douglas Fairlie

W. Douglas Fairlie is a scholar working on Immunology, Molecular Biology and Parasitology, having authored 103 papers that have together received 8.7k indexed citations. Recurring topics across this work include Cell death mechanisms and regulation (37 papers), RNA Interference and Gene Delivery (17 papers) and GDF15 and Related Biomarkers (11 papers). The work is most often cited by research in Rheumatology (1.8k citations), Immunology (2.4k citations) and Molecular Biology (5.6k citations). W. Douglas Fairlie has collaborated with scholars based in Australia, United States and Italy. Frequent co-authors include Erinna F. Lee, David C.S. Huang, Samuel N. Breit, Peter E. Czabotar, Peter M. Colman, Asne R. Bauskin, Brian J. Smith, Philippe Bouillet, Andreas Strasser and Mark F. van Delft. Their work appears in journals such as Nature, Science and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact